Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashFree Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for Spyre Therapeutics (SYRE) over the last 11 years, with Q3 2025 value amounting to $9.6 million.

  • Spyre Therapeutics' Share-based Compensation fell 2697.71% to $9.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $37.0 million, marking a year-over-year decrease of 3002.74%. This contributed to the annual value of $44.8 million for FY2024, which is 7461.73% up from last year.
  • Per Spyre Therapeutics' latest filing, its Share-based Compensation stood at $9.6 million for Q3 2025, which was down 2697.71% from $9.4 million recorded in Q2 2025.
  • Spyre Therapeutics' 5-year Share-based Compensation high stood at $17.3 million for Q4 2023, and its period low was $1.4 million during Q4 2022.
  • Moreover, its 5-year median value for Share-based Compensation was $2.1 million (2021), whereas its average is $6.0 million.
  • As far as peak fluctuations go, Spyre Therapeutics' Share-based Compensation surged by 111023.13% in 2023, and later crashed by 4663.58% in 2024.
  • Quarter analysis of 5 years shows Spyre Therapeutics' Share-based Compensation stood at $2.1 million in 2021, then tumbled by 31.85% to $1.4 million in 2022, then skyrocketed by 1110.23% to $17.3 million in 2023, then plummeted by 46.64% to $9.2 million in 2024, then increased by 3.8% to $9.6 million in 2025.
  • Its Share-based Compensation stands at $9.6 million for Q3 2025, versus $9.4 million for Q2 2025 and $8.9 million for Q1 2025.